Ahmad Albshesh, Shadi Haj, Ido Veisman, Lior Dar, Shomron Ben-Horin, Ohad Regev, Uri Kopylov, Dan Carter
{"title":"肠超声测量肠壁厚度可作为判定克罗恩病抗肿瘤坏死因子维持治疗失败的唯一标志。","authors":"Ahmad Albshesh, Shadi Haj, Ido Veisman, Lior Dar, Shomron Ben-Horin, Ohad Regev, Uri Kopylov, Dan Carter","doi":"10.1177/17562848251343008","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Bowel wall thickness (BWT) measurements in intestinal ultrasound (IUS) are recognized indicators of inflammatory activity in Crohn's disease (CD). However, the added value of other ultrasonographic parameters for monitoring and predicting treatment failure during anti-tumor necrosis factors' (TNF) maintenance therapy is still not absolutely defined.</p><p><strong>Objectives: </strong>To determine whether BWT, as measured by IUS, can serve as a reliable single marker for predicting treatment failure in CD patients under anti-TNF therapy, compared to a combination of ultrasonographic parameters.</p><p><strong>Design: </strong>This study was a single-center, retrospective cohort study.</p><p><strong>Methods: </strong>This study included 103 CD patients in clinical remission on anti-TNF therapy, who had an IUS examination within 10 months following therapy initiation. We investigated the correlation of these ultrasonographic parameters with subsequent treatment failures, defined by disease flares, and the need for surgery, hospitalization, corticosteroid use, dose escalation, and drug discontinuation.</p><p><strong>Results: </strong>Treatment failure occurred in 59.2% of patients within a median of 5 months post-index IUS. Significant differences were observed in BWT (3.9 mm in the failure group vs 3 mm in the remission group, <i>p</i> = 0.007), bowel wall flow (BWF; 49.2% vs 23.8%, <i>p</i> = 0.009), and mesenteric hypertrophy (20.4% vs 7.1%, <i>p</i> = 0.006). In receiver operating characteristic analysis for BWT, the area under the curve (AUC) of BWT >3 mm was 0.66, with a sensitivity of 67.2% and specificity of 69.1%. The combined (BWT, BWF, and mesenteric hypertrophy) AUC was 0.68 (sensitivity of 62.9%, specificity of 61.9%). Delong's test showed no significant difference in AUC (<i>p</i> = 0.137). BWT emerged as the most significant parameter in stepwise regression analysis.</p><p><strong>Conclusion: </strong>Our findings suggest that BWT alone may be used as a single ultrasonographic marker of treatment, therefore simplifying the use of IUS. Using a single objective ultrasonographic parameter simplifies the use of IUS, an important factor that can facilitate the use of this important imaging technique.</p>","PeriodicalId":48770,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"18 ","pages":"17562848251343008"},"PeriodicalIF":3.9000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149615/pdf/","citationCount":"0","resultStr":"{\"title\":\"Intestinal ultrasound measurement of bowel wall thickness can be used as a sole marker for defining anti-TNF maintenance therapy failure in Crohn's disease.\",\"authors\":\"Ahmad Albshesh, Shadi Haj, Ido Veisman, Lior Dar, Shomron Ben-Horin, Ohad Regev, Uri Kopylov, Dan Carter\",\"doi\":\"10.1177/17562848251343008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Bowel wall thickness (BWT) measurements in intestinal ultrasound (IUS) are recognized indicators of inflammatory activity in Crohn's disease (CD). However, the added value of other ultrasonographic parameters for monitoring and predicting treatment failure during anti-tumor necrosis factors' (TNF) maintenance therapy is still not absolutely defined.</p><p><strong>Objectives: </strong>To determine whether BWT, as measured by IUS, can serve as a reliable single marker for predicting treatment failure in CD patients under anti-TNF therapy, compared to a combination of ultrasonographic parameters.</p><p><strong>Design: </strong>This study was a single-center, retrospective cohort study.</p><p><strong>Methods: </strong>This study included 103 CD patients in clinical remission on anti-TNF therapy, who had an IUS examination within 10 months following therapy initiation. We investigated the correlation of these ultrasonographic parameters with subsequent treatment failures, defined by disease flares, and the need for surgery, hospitalization, corticosteroid use, dose escalation, and drug discontinuation.</p><p><strong>Results: </strong>Treatment failure occurred in 59.2% of patients within a median of 5 months post-index IUS. Significant differences were observed in BWT (3.9 mm in the failure group vs 3 mm in the remission group, <i>p</i> = 0.007), bowel wall flow (BWF; 49.2% vs 23.8%, <i>p</i> = 0.009), and mesenteric hypertrophy (20.4% vs 7.1%, <i>p</i> = 0.006). In receiver operating characteristic analysis for BWT, the area under the curve (AUC) of BWT >3 mm was 0.66, with a sensitivity of 67.2% and specificity of 69.1%. The combined (BWT, BWF, and mesenteric hypertrophy) AUC was 0.68 (sensitivity of 62.9%, specificity of 61.9%). Delong's test showed no significant difference in AUC (<i>p</i> = 0.137). BWT emerged as the most significant parameter in stepwise regression analysis.</p><p><strong>Conclusion: </strong>Our findings suggest that BWT alone may be used as a single ultrasonographic marker of treatment, therefore simplifying the use of IUS. Using a single objective ultrasonographic parameter simplifies the use of IUS, an important factor that can facilitate the use of this important imaging technique.</p>\",\"PeriodicalId\":48770,\"journal\":{\"name\":\"Therapeutic Advances in Gastroenterology\",\"volume\":\"18 \",\"pages\":\"17562848251343008\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149615/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17562848251343008\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848251343008","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
肠超声(IUS)测量肠壁厚度(BWT)是克罗恩病(CD)炎症活动的公认指标。然而,在抗肿瘤坏死因子(TNF)维持治疗中,其他超声参数对监测和预测治疗失败的附加价值仍未完全确定。目的:与超声参数组合相比,确定IUS测量的BWT是否可以作为预测抗tnf治疗下CD患者治疗失败的可靠单一指标。设计:本研究为单中心、回顾性队列研究。方法:本研究纳入103例经抗肿瘤坏死因子治疗后临床缓解的CD患者,这些患者在治疗开始后10个月内进行了IUS检查。我们研究了这些超声参数与随后治疗失败的相关性,治疗失败的定义是疾病发作、手术、住院、皮质类固醇使用、剂量增加和停药的需要。结果:59.2%的患者在指数IUS后中位5个月内出现治疗失败。BWT(失败组3.9 mm vs缓解组3 mm, p = 0.007)、肠壁流量(BWF;49.2% vs 23.8%, p = 0.009)和肠系膜肥厚(20.4% vs 7.1%, p = 0.006)。在BWT患者工作特征分析中,BWT >3 mm的曲线下面积(AUC)为0.66,敏感性为67.2%,特异性为69.1%。合并(BWT、BWF和肠系膜肥厚)AUC为0.68(敏感性62.9%,特异性61.9%)。Delong检验显示AUC差异无统计学意义(p = 0.137)。BWT是逐步回归分析中最显著的参数。结论:我们的研究结果提示单独BWT可作为治疗的单一超声标记,从而简化IUS的使用。使用单一物镜超声参数简化了IUS的使用,这是促进这项重要成像技术使用的重要因素。
Intestinal ultrasound measurement of bowel wall thickness can be used as a sole marker for defining anti-TNF maintenance therapy failure in Crohn's disease.
Introduction: Bowel wall thickness (BWT) measurements in intestinal ultrasound (IUS) are recognized indicators of inflammatory activity in Crohn's disease (CD). However, the added value of other ultrasonographic parameters for monitoring and predicting treatment failure during anti-tumor necrosis factors' (TNF) maintenance therapy is still not absolutely defined.
Objectives: To determine whether BWT, as measured by IUS, can serve as a reliable single marker for predicting treatment failure in CD patients under anti-TNF therapy, compared to a combination of ultrasonographic parameters.
Design: This study was a single-center, retrospective cohort study.
Methods: This study included 103 CD patients in clinical remission on anti-TNF therapy, who had an IUS examination within 10 months following therapy initiation. We investigated the correlation of these ultrasonographic parameters with subsequent treatment failures, defined by disease flares, and the need for surgery, hospitalization, corticosteroid use, dose escalation, and drug discontinuation.
Results: Treatment failure occurred in 59.2% of patients within a median of 5 months post-index IUS. Significant differences were observed in BWT (3.9 mm in the failure group vs 3 mm in the remission group, p = 0.007), bowel wall flow (BWF; 49.2% vs 23.8%, p = 0.009), and mesenteric hypertrophy (20.4% vs 7.1%, p = 0.006). In receiver operating characteristic analysis for BWT, the area under the curve (AUC) of BWT >3 mm was 0.66, with a sensitivity of 67.2% and specificity of 69.1%. The combined (BWT, BWF, and mesenteric hypertrophy) AUC was 0.68 (sensitivity of 62.9%, specificity of 61.9%). Delong's test showed no significant difference in AUC (p = 0.137). BWT emerged as the most significant parameter in stepwise regression analysis.
Conclusion: Our findings suggest that BWT alone may be used as a single ultrasonographic marker of treatment, therefore simplifying the use of IUS. Using a single objective ultrasonographic parameter simplifies the use of IUS, an important factor that can facilitate the use of this important imaging technique.
期刊介绍:
Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.
The editors welcome original research articles across all areas of gastroenterology and hepatology.
The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.